WEBULL
WebtradeDownload

Teleflex (TFX) Could Be 20% Undervalued After New Infection Study

Simply Wall St · 4d ago

Teleflex (TFX) is back in focus after publishing new peer-reviewed data showing its Arrowg+ard central venous catheters were linked with a 70% lower hazard of central line-associated bloodstream infections in critically ill patients.

The new infection control data arrives at a time when Teleflex shares have been under pressure in the short term, with the 30 day share price return down 10.29% and the 90 day share price return down 7.05%. However, the year to date share price return remains positive at 1.41%.

Look beyond Teleflex to see how other infection control and medical device specialists compare in our curated list of 31 resilient stocks with low risk scores.

Teleflex now has fresh clinical proof in its corner, yet the share price has slipped in recent months. The next step is simple: Does the current valuation still treat this as a strong business on sale?

Most Popular Narrative: 20% Undervalued

The most followed narrative currently values Teleflex at $154.73 per share, compared with a last close of $124.12. This frames a material valuation gap for investors to assess.

The portfolio shift toward a more focused Teleflex RemainCo, following the sale of the OEM business and planned exits from additional noncore units, is expected to concentrate resources in Vascular, Interventional and Surgical segments and support higher revenue contribution from acute care and high acuity hospital procedures.

See why 8 investors see Teleflex as 20% undervalued.

Result: Fair Value of $154.73 (UNDERVALUED)

Still, the Teleflex narrative can break if BIOTRONIK integration slows Interventional growth or if cost savings and stranded cost offsets arrive slower than planned.

Find out about the key risks to this Teleflex narrative.

Another View on Teleflex Valuation

On multiples, Teleflex screens as expensive against its own history, with a P/S ratio of 2.3x versus a fair ratio of 2x and peer average of 1.9x. That points to less margin for error if execution slips, so how much weight should investors give to this richer pricing signal?

See what the numbers say about this price — find out in our valuation breakdown.

NYSE:TFX P/S Ratio as at Oct 2026
NYSE:TFX P/S Ratio as at Oct 2026

Next Steps

Mixed messages around Teleflex can feel confusing, so move fast, review the underlying numbers and clinical evidence, then weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Teleflex?

Do not stop your research with Teleflex. Broaden your watchlist with fresh opportunities that match your risk profile, income goals, and appetite for underappreciated businesses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.